Jazz Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
3,627
- Stock Symbol
-
JAZZ
- Investments
-
22
- Share Price
-
$230.80
- (As of Friday Closing)
Jazz Pharmaceuticals General Information
Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact Information
Website
www.jazzpharma.comCorporate Office
- Waterloo Exchange
- Waterloo Road
- Dublin D04 E5W7
- Ireland
Corporate Office
- Waterloo Exchange
- Waterloo Road
- Dublin D04 E5W7
- Ireland
Jazz Pharmaceuticals Timeline
Jazz Pharmaceuticals Stock Performance
As of 20-Nov-2026, Jazz Pharmaceuticals’s stock price is $230.80. Its current market cap is $14.8B with 64.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $230.80 | $236.45 | $156.95 - $266.38 | $14.8B | 64.2M | 899K | $3.37 |
Jazz Pharmaceuticals Financials Summary
As of 30-Sep-2026, Jazz Pharmaceuticals has a trailing 12-month revenue of $4.72B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,238,523 | 13,712,525 | 11,028,868 | 11,951,888 |
| Revenue | 4,718,186 | 4,267,586 | 4,068,950 | 3,834,204 |
| EBITDA | 1,146,289 | 263,489 | 1,368,515 | 1,226,063 |
| Net Income | 205,952 | (356,148) | 560,120 | 414,832 |
| Total Assets | 11,997,700 | 11,659,340 | 12,012,257 | 11,393,359 |
| Total Debt | 5,645,000 | 5,423,866 | 6,162,357 | 5,791,614 |
Jazz Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jazz Pharmaceuticals Comparisons
Industry
Financing
Details
Jazz Pharmaceuticals Competitors (25)
One of Jazz Pharmaceuticals’s 25 competitors is Gilead, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Jazz Pharmaceuticals Patents
Jazz Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026210449-A1 | Compounds for tmem175 modulation | Pending | 04-Apr-2025 | ||
| WO-2026207484-A1 | Pharmaceutical compositions and uses thereof for the treatment of pcpg: pheochromocytomas and paragangliomas | Pending | 28-Mar-2025 | ||
| US-20260265252-A1 | Solid state forms of imipridone derivative | Pending | 28-May-2024 | ||
| WO-2025163494-A1 | Condensed azines for the treatment of cancer | Pending | 29-Jan-2024 | ||
| WO-2025019344-A2 | Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof | Inactive | 14-Jul-2023 | A61K31/454 |
Jazz Pharmaceuticals Signals
Jazz Pharmaceuticals Investments & Acquisitions (22)
Jazz Pharmaceuticals’s most recent deal was a Early Stage VC with Setara Biosciences for . The deal was made on 30-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Setara Biosciences | 30-Oct-2026 | Early Stage VC | Biotechnology | ||
| Actio Biosciences | 15-Sep-2026 | Merger/Acquisition | Drug Discovery | ||
| Saniona (SAN2355 License) | 20-Aug-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Chimerix | 21-Apr-2025 | Merger/Acquisition | Drug Discovery | ||
| Redx Pharma (Kirsten Rat Sarcoma Virus Inhibitor Program in Macclesfield, United Kingdom) | 07-Feb-2024 | Corporate Asset Purchase | Drug Discovery |
Jazz Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.69 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Jazz Pharmaceuticals Exits (2)
Jazz Pharmaceuticals’s most recent exit was on 12-Jun-2012 from EUSA Pharma (UK). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| EUSA Pharma (UK) | 12-Jun-2012 | Completed |
|
||
| Prialt | 05-May-2010 | Merger/Acquisition | Completed |
Jazz Pharmaceuticals Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Actio Biosciences | San Diego, CA | 2021 | |
| Jazz Pharmaceuticals Ireland Holdings | Dublin, Ireland | 2019 | |
| Gw Pharma (Germany) | Munich, Germany | 2018 | |
| Gw Pharma (International) | Amersfoort, Netherlands | 2018 | |
| Jazz Financing Uk | London, United Kingdom | 2011 |
Jazz Pharmaceuticals FAQs
-
When was Jazz Pharmaceuticals founded?
Jazz Pharmaceuticals was founded in 2003.
-
Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
-
What is the size of Jazz Pharmaceuticals?
Jazz Pharmaceuticals has 3,627 total employees.
-
What industry is Jazz Pharmaceuticals in?
Jazz Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Jazz Pharmaceuticals a private or public company?
Jazz Pharmaceuticals is a Public company.
-
What is Jazz Pharmaceuticals’s stock symbol?
The ticker symbol for Jazz Pharmaceuticals is JAZZ.
-
What is the current stock price of Jazz Pharmaceuticals?
As of 20-Nov-2026 the stock price of Jazz Pharmaceuticals is $230.80.
-
What is the current market cap of Jazz Pharmaceuticals?
The current market capitalization of Jazz Pharmaceuticals is $14.8B.
-
What is Jazz Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Jazz Pharmaceuticals is $4.72B.
-
Who are Jazz Pharmaceuticals’s competitors?
Gilead, Regeneron Pharmaceuticals, Amgen, Harmony Biosciences Holdings, and Sarepta Therapeutics are some of the 25 competitors of Jazz Pharmaceuticals.
-
What is Jazz Pharmaceuticals’s annual earnings per share (EPS)?
Jazz Pharmaceuticals’s EPS for 12 months was $3.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process